<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196335</url>
  </required_header>
  <id_info>
    <org_study_id>S2459</org_study_id>
    <nct_id>NCT04196335</nct_id>
  </id_info>
  <brief_title>I Can sEe Left Atrial Appendage (ICELAA) Clinical Study</brief_title>
  <acronym>ICELAA</acronym>
  <official_title>I Can sEe Left Atrial Appendage (ICELAA) Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy and safety of using&#xD;
      intra-procedural intracardiac echocardiography (ICE) for WATCHMAN FLX Device implants in&#xD;
      subjects with non-valvular atrial fibrillation to reduce the risk of stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant leak (&gt;5 mm) as assessed by TEE at 45 days' post-implant.</measure>
    <time_frame>45 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Efficacy, Self</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intra-procedural intracardiac echocardiography</intervention_name>
    <description>use of intra-procedural intracardiac echocardiography during Watchman FLX devices</description>
    <arm_group_label>single-arm</arm_group_label>
    <other_name>Watchman FLX Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is of legal age to participate in the study per the laws of their&#xD;
             respective geography;&#xD;
&#xD;
          2. The subject has documented paroxysmal, persistent, permanent or long-term/longstanding&#xD;
             persistent non-valvular atrial fibrillation (i.e., the subject does not have mitral&#xD;
             stenosis or a mechanical heart valve);the subject has not been diagnosed with&#xD;
             rheumatic mitral valvular heart disease);&#xD;
&#xD;
          3. The subject is deemed by the treating physician to be suitable for the protocol&#xD;
             defined pharmacologic regimens;&#xD;
&#xD;
          4. The subject has a calculated CHA2DS2-VASc score of 2 or greater;&#xD;
&#xD;
          5. The subject is able to undergo ICE examinations;The subject is able to undergo&#xD;
             ICE(which will be used during the index procedure) and TEE (which will be performed at&#xD;
             45 days and may also be performed at baseline);&#xD;
&#xD;
          6. The subject is able to understand and willing to provide written informed consent to&#xD;
             participate in the trial;&#xD;
&#xD;
          7. The subject is able and willing to return for required follow-up visits and&#xD;
             examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are currently enrolled in another investigational study or registry that&#xD;
             would directly interfere with the current study, except when the subject is&#xD;
             participating in a mandatory governmental registry, or a purely observational registry&#xD;
             with no associated treatments. Each instance must be brought to the attention of the&#xD;
             sponsor to determine eligibility, regardless of type of co-enrollment being proposed;&#xD;
&#xD;
          2. The subject requires long-term anticoagulation therapy for reasons other than&#xD;
             AF-related stroke risk reduction, for example due to an underlying hypercoaguable&#xD;
             state (i.e., even if the device is implanted, the subjects would not be eligible to&#xD;
             discontinue OAC due to other medical conditions requiring chronic warfarin therapy);&#xD;
&#xD;
          3. The subject has a history of atrial septal repair or has an ASD/PFO device;&#xD;
&#xD;
          4. The subject has an implanted mechanical valve prosthesis in any position;&#xD;
&#xD;
          5. The subject currently or has had any documented history of, New York Heart Association&#xD;
             Class IV Congestive Heart Failure;&#xD;
&#xD;
          6. The subject is of childbearing potential and is or plans to become pregnant during the&#xD;
             time of the study (method of assessment upon study physician's discretion).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valerie Lens</last_name>
    <phone>+32491153990</phone>
    <email>valerie.Lens@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Skejby</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens-Erik Nielsen-Kudsk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele Monasterio</name>
      <address>
        <city>Massa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Berti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederico Ronco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Fondazione Monzino</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Caprioglio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Radcliffe</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

